X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (26) 26
index medicus (24) 24
female (19) 19
hematology (19) 19
male (19) 19
middle aged (19) 19
adult (18) 18
transplantation, homologous (10) 10
aged (9) 9
abridged index medicus (8) 8
adolescent (8) 8
transplantation (8) 8
oncology (7) 7
retrospective studies (7) 7
stem cell transplantation (7) 7
bone marrow transplantation (6) 6
bone-marrow transplantation (6) 6
bone-marrow-transplantation (6) 6
cancer (6) 6
hematopoietic stem cell transplantation (6) 6
prognosis (6) 6
stem cells (6) 6
treatment outcome (6) 6
child (5) 5
chronic myelogenous leukemia (5) 5
disease (5) 5
disease-free survival (5) 5
graft vs host disease - immunology (5) 5
hematopoietic stem cell transplantation - adverse effects (5) 5
histocompatibility (5) 5
recurrence (5) 5
survival analysis (5) 5
therapy (5) 5
chronic myeloid leukemia (4) 4
leukemia (4) 4
leukemia, myelogenous, chronic, bcr-abl positive - therapy (4) 4
myelodysplastic syndrome (4) 4
stem-cell transplantation (4) 4
survival (4) 4
young adult (4) 4
acute disease (3) 3
allogeneic transplantation (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
child, preschool (3) 3
cohort studies (3) 3
cytarabine - administration & dosage (3) 3
cytokine (3) 3
follow-up studies (3) 3
graft vs host disease - etiology (3) 3
graft vs host disease - pathology (3) 3
hematopoietic stem cells (3) 3
imatinib mesylate (3) 3
interferon (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (3) 3
lymphoma, follicular - therapy (3) 3
mlc (3) 3
mortality (3) 3
multivariate analysis (3) 3
piperazines - administration & dosage (3) 3
pyrimidines - administration & dosage (3) 3
research (3) 3
t-lymphocytes - immunology (3) 3
tissue donors (3) 3
transplantation conditioning (3) 3
transplants & implants (3) 3
tyrosine kinase inhibitor (3) 3
versus-host disease (3) 3
acute myelogenous leukemia (2) 2
acute myeloid-leukemia (2) 2
age factors (2) 2
aml (2) 2
antigens, cd34 - biosynthesis (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
b-cell lymphoma (2) 2
benzamides (2) 2
blood (2) 2
bone marrow (2) 2
care and treatment (2) 2
chain immunotoxin (2) 2
clinical trials (2) 2
cytarabine (2) 2
cytarabine - adverse effects (2) 2
cytogenetic analysis (2) 2
dose-response relationship, drug (2) 2
drug therapy, combination (2) 2
europe (2) 2
expression (2) 2
follicular lymphoma (2) 2
genetic linkage (2) 2
graft (2) 2
graft vs host disease - mortality (2) 2
graft vs leukemia effect (2) 2
helper (2) 2
hematology, oncology and palliative medicine (2) 2
hematopoietic stem cell transplantation - mortality (2) 2
histocompatibility testing - methods (2) 2
identification (2) 2
imatinib (2) 2
immunology (2) 2
immunotoxins - pharmacokinetics (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 06/2014, Volume 311, Issue 24, pp. 2490 - 2498
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 2005, Volume 115, Issue 12, pp. 3506 - 3516
Minor histocompatibility antigens (mHAgs) constitute the targets of the graft-versus-leukemia response after HLA-identical allogeneic stem cell... 
MEDICINE, RESEARCH & EXPERIMENTAL | MINOR HISTOCOMPATIBILITY ANTIGEN | FEASIBILITY | RECOGNITION | H-Y | DIALLELIC GENE | STEM-CELL TRANSPLANTATION | IDENTIFICATION | RECEPTORS | CONTAINS | EXPRESSION | Recurrence | Frameshift Mutation | Humans | Male | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Interferon-gamma - metabolism | Lod Score | Stem Cell Transplantation | Stem Cells | Retroviridae - genetics | Time Factors | Base Sequence | CD8-Positive T-Lymphocytes - metabolism | Neurons - metabolism | HLA-B Antigens - chemistry | Amino Acid Sequence | Antigens, CD34 - biosynthesis | HLA-B7 Antigen | Genotype | Chromosome Mapping | Genetic Markers | Chromium - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Plasmids - metabolism | Polymorphism, Genetic | Receptors, Purinergic P2 - metabolism | T-Lymphocytes - immunology | Epitopes - chemistry | Models, Genetic | T-Lymphocytes, Cytotoxic - cytology | Haplotypes | Leukocyte Common Antigens - chemistry | Molecular Sequence Data | Transplantation, Homologous | Receptors, Purinergic P2 - genetics | Adult | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology | Genetic Linkage | Fusion Proteins, bcr-abl - chemistry | Cell Line | Peptides - chemistry | Bone Marrow Cells - cytology | Cells, Cultured | Transcription Factors - genetics | DNA-Binding Proteins - genetics | Homozygote | Graft vs Leukemia Effect | Chromosomes, Human, Pair 17 | T-Lymphocytes - cytology | Pedigree | Receptors, Purinergic P2X5 | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 06/2010, Volume 95, Issue 6, pp. 914 - 921
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 6, pp. 1054 - 1058
Journal Article
Journal Article
Blood, ISSN 0006-4971, 2008, Volume 111, Issue 5, pp. 2581 - 2588
The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase... 
CHRONIC MYELOGENOUS LEUKEMIA | MESYLATE | CHROMOSOME | INTERFERON | CHRONIC-PHASE | RECOMMENDATIONS | TYROSINE KINASE INHIBITOR | NEUTROPENIC PATIENTS | BRAIN-ABSCESS | HEMATOLOGY | FEATURES | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Cytarabine - therapeutic use | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Hematologic Tests | Antineoplastic Agents - administration & dosage | Cytarabine - adverse effects | Feasibility Studies | Dose-Response Relationship, Drug | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Antineoplastic Agents - adverse effects | Adult | Female | Cytogenetic Analysis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Pyrimidines - administration & dosage | Mortality | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Cytarabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Benzamides | Communicable Diseases - complications | Index Medicus | Abridged Index Medicus
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2008, Volume 71, Issue 5, pp. 1444 - 1454
Purpose To evaluate results of high-dose total-body irradiation (TBI) regimens for hematopoietic stem cell transplantation. Methods and Materials A total of... 
Radiology | Hematology, Oncology and Palliative Medicine | Late effects | Treatment results | Dose–effect relationships | Total-body irradiation | Hematopoietic stem cell transplantation | Dose-effect relationships | BUSULFAN-CYCLOPHOSPHAMIDE | BONE-MARROW-TRANSPLANTATION | 1ST REMISSION | treatment results | RANDOMIZED-TRIAL | ACUTE MYELOID-LEUKEMIA | dose-effect relationships | ACUTE MYELOBLASTIC-LEUKEMIA | total-body irradiation | REDUCED-INTENSITY | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | hematopoietic stem cell transplantation | RETROSPECTIVE ANALYSIS | HEMATOLOGIC MALIGNANCIES | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | late effects | Recurrence | Acute Disease | Whole-Body Irradiation - mortality | Age Factors | Humans | Middle Aged | Leukemia - therapy | Male | Treatment Outcome | Hematopoietic Stem Cell Transplantation - mortality | Radiation Protection - methods | Disease-Free Survival | Netherlands | Analysis of Variance | Lymphoma, Non-Hodgkin - therapy | Adolescent | Sex Factors | Adult | Female | Lymphoma, Non-Hodgkin - mortality | Relative Biological Effectiveness | Transplantation Conditioning | Leukemia - mortality | Transplantation | Hematopoietic stem cells | Stem cells | Index Medicus | LYMPHOMAS | MORTALITY | PATIENTS | SHIELDING | WHOLE-BODY IRRADIATION | RADIOLOGY AND NUCLEAR MEDICINE | RADIATION DOSES | STEM CELLS | LEUKEMIA | RADIOTHERAPY
Journal Article
Haematologica, ISSN 0390-6078, 06/2010, Volume 95, Issue 6, pp. 914 - 921
Background In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and... 
Journal Article
Journal Article
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, ISSN 0360-3016, 08/2008, Volume 71, Issue 5, pp. 1444 - 1454
Purpose: To evaluate results of high-dose total-body irradiation (TBI) regimens for hematopoietic stem cell transplantation. Methods and Materials: A total of... 
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2000, Volume 111, Issue 2, p. 685
Journal Article
Blood, ISSN 0006-4971, 03/2008, Volume 111, Issue 5, pp. 2581 - 2588
The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase... 
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/1999, Volume 105, Issue 2, pp. 340 - 348
Selection procedures in bone marrow transplantation (BMT) would benefit from the development of easy-to-perform cellular assays with high discriminative power.... 
cytokine | interferon-γ | MLC | histocompatibility | bone marrow transplantation
Journal Article